Conference Correspondent

ASH 2016 - Multiple Myeloma

As more patients receive maintenance therapy for multiple myeloma, researchers seek to evaluate the impact of toxicities associated with long-term treatment on health-related quality of life in these patient populations.

Recent data showed that lenalidomide maintenance therapy is an effective option for both transplant-eligible and nontransplant-eligible patients with multiple myeloma.

The majority of patients with smoldering multiple myeloma do not receive active treatment. In this study, treatment of a high-risk population with lenalidomide and dexamethasone yielded favorable patient outcomes.

Investigational agents with novel mechanisms of action continue to show promise in treating multiple myeloma. In this study, researchers report findings of a phase 1a/1b study evaluating an oral HDAC6 inhibitor.

Healthcare stakeholders have formulated a number of management approaches to ensure that patients receive appropriate therapies. Here, clinicians at Cleveland Clinic report on a response-adapted treatment protocol for newly diagnosed patients with multiple myeloma.

This phase 2 study of elotuzumab, lenalidomide, and dexamethasone combination therapy in a high-risk population of patients with smoldering multiple myeloma showed promising efficacy and tolerability.

New treatment approaches are needed in multiple myeloma to extend relapse-free intervals and overall survival. In a phase 1/2 trial, the combination of pomalidomide, dexamethasone, and weekly carfilzomib showed impressive efficacy with acceptable tolerability.

In this analysis, Connect MM, a large observational disease registry, was used to characterize evolving treatment patterns and outcomes for patients with newly diagnosed multiple myeloma.

Recent study findings presented at the ASH 2016 Annual Meeting suggest that pomalidomide and low-dose dexamethasone can be used immediately following lenalidomide-based therapy to treat patients with relapsed/refractory multiple myeloma.

Page 2 of 2
Results 11 - 19 of 19
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • National Association of Specialty Pharmacy
  • Lynx CME